Alendronate Sodium Tablet
Product Images NDC 69097-224

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 69097-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 01

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 02

This is a graph showing the cumulative incidence of hip fractures in patients with radiographic vertebral fracture at baseline over a three-year study of FIT. The graph presents two types of patients: those who received placebo treatment and those who were treated with Alendronate Sodium. The X-axis shows the time in months and the Y-axis represents the cumulative incidence of hip fractures in percentages.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 03

This text seems to provide results from a study on the treatment of osteoporosis in postmenopausal women, with a focus on the increase in bone mineral density (BMD) over three years using alendronate sodium at a 10 mg/day dose. The text also lists numerical values for BMD in different areas of the body, such as the lumbar spine, femoral neck, and trochanter.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 04

Osteoporosis Treatment Studies in Postmenopausal women with Alendronate Sodium 10 mg/day Versus Placebo showed a time course of effect on Lumbar Spine BMD percent change from baseline in both US and multinational study groups. The mean percentage change in BMD from baseline was recorded over a course of 37-72 months.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 05

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 06

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 07

This is a description of a study on the impact of Alendronate Sodium 40mg/day on Paget's Disease of Bone, as compared to a placebo or Etidronate 400mg/day. The study included 27 participants and measured the effect on serum alkaline phosphatase levels over time. The results are presented in a graph showing the mean percentage change from baseline levels for each treatment group over a period of months.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 08

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 09

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.